Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.87 USD

29.87
26,896,912

+0.37 (1.25%)

Updated Jul 17, 2024 09:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now

by Kinjel Shah

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $27.41, marking a +1.59% move from the previous day.

Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval

by Zacks Equity Research

Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.

Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.

Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal

by Zacks Equity Research

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails

by Kinjel Shah

An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.

Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal

by Zacks Equity Research

Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.

Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

Pfizer (PFE) closed at $27.66 in the latest trading session, marking a -1.32% move from the prior day.

Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal

by Zacks Equity Research

Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.

Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

by Zacks Equity Research

Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years

by Zacks Equity Research

GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.

AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal

by Zacks Equity Research

Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.

AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug

by Zacks Equity Research

The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.

Sundeep Ganoria headshot

FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains

by Sundeep Ganoria

An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.

GSK Stock Dips on Delaware Court Ruling for Zantac Litigation

by Zacks Equity Research

GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.

Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine

by Zacks Equity Research

The RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.

Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Kinjel Shah headshot

Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More

by Kinjel Shah

AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

by Zacks Equity Research

This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.

Sundeep Ganoria headshot

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

by Sundeep Ganoria

The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

Pfizer (PFE) Recently Broke Out Above the 200-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 200-day simple moving average?

Why Novavax (NVAX) Stock Price Appreciated 14% on Monday

by Zacks Equity Research

Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company???s recently signed multi-billion-dollar deal with Sanofi.